Z-VAD-FMK

Catalog No.S7023

Z-VAD-FMK Chemical Structure

Molecular Weight(MW): 467.49

Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.

Size Price Stock Quantity  
USD 117 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

6 Customer Reviews

  • (A) LAN5 cells were untreated (top panels) or treated with 50 µM of the caspase inhibitor Z-VAD-FMK (bottom panels). Cells were co-treated with nothing (No Rx), 1 µM GSK-J4, or 1 µM venetoclax for 48 hours and assayed for apoptosis by flow cytometry.

    Science, 2018, 10(441), doi: 10.1126/scitranslmed.aao4680. Z-VAD-FMK purchased from Selleck.

    After treatment with 1.5 g/l matrine in the presence or absence of 10 nM Baf A1 or 20 nM rapamycin or 10 lM z-VAD-FMK (zVAD) for 24 hrs, the cell viability was measured by CCK-8 assay. Results were expressed as mean±S.E.M. representing at least three independent experiments. *P < 0.05, versus matrine alone group.

    J Cell Mol Med, 2017, 21(6):1171-1181. Z-VAD-FMK purchased from Selleck.

  • Z-VAD-FMK (ZVF) reversed K562 cell apoptosis induced by imatinib (IM) and/or hUC-MSCs-Exo. **P < 0.01 versus K562 + IM group, ##P < 0.01 versus K562 + IM + hUC-MSC-Exo group.

    Cytotherapy, 2018, 20(2):181-188. Z-VAD-FMK purchased from Selleck.

    (A and B) Western blot analysis examining the effect of zVAD-fmk on the icaritin-induced apoptosis. The caspase inhibitor zVAD-fmk could significantly decrease the icaritin-induced cleaved caspase-3 expression. β-Actin protein levels indicate that an equal amount of protein was loaded into each lane.n=3. Mean±SD. bP<0.05, compared to the control group. eP<0.05, compared to the icaritin-treated group.

    Acta Pharmacol Sin 2014 35(4):531-9. Z-VAD-FMK purchased from Selleck.

  • Active caspase-3 expression analysis. SW1116 cells were treated with ZBH-1205, CPT-11 and SN38 at 25 μmol/L for 48 h, in the presence or absence of Z-VAD-FMK (50 μmol/L, 1 h ahead of time). *P= 0.0345. Z-VAD-FMK(-) vs. Z-VAD-FMK(+). E: Cell cycle analysis. F: Apoptosis analysis. #P=0.0259. Z-VAD-FMK(-) vs. Z-VAD-FMK(+). ALL experiments were repeated three times.

    Arch Biochem Biophys, 2016, 604:74-85.. Z-VAD-FMK purchased from Selleck.

    Effect on the RAS of CFZ, z-VAD-fmk, or CFZ + z-VAD-fmk treatments administered 5 or 12 days after C26 inoculation and control groups. Western blot analysis of ATF2 and pATF2. CP, ZP and UP were treated for 5 days; CT, ZT, UT and CC were treated for 12 days. CFZ (CP), z-VAD-fmk (ZP), CFZ + z-VAD-fmk (UP), PBS only (CC), healthy control (HC).

    Med Oncol, 2015, 32(4): 538 . Z-VAD-FMK purchased from Selleck.

Purity & Quality Control

Choose Selective Caspase Inhibitors

Biological Activity

Description Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.
Features A key compound for apoptosis studies.
Targets
Pan-caspase [1]
(THP.1, Jurkat T-cells)
In vitro

Z-VAD-FMK (10 mM) inhibits apoptosis in THP.1 cells. Z-VAD-FMK (10 μM) inhibits activation of PARP protease activity in control THP.1 cell lysates. Z-VAD-FMK (10 mM) inhibits the processing of CPP32 in intact THP.1 and Jurkat cells. [1] Z-VAD-FMK (50 μM) cotreatment abolishes the apoptotic morphology of camptothecin-treated HL60 cells. Z-VAD-FMK (50 μM) blocks camptothecin-induced DNA fragmentation in HL60 cells. [2] Z-VAD-FMK (50 μM) inhibits cell death following dSMN dsRNA-induced apoptosis in S2 cells. Z-VAD-FMK (50 μM) increases the percentage of transfected cells surviving from 26% to 63% in S2 cells. [3] Z-VAD-FMK (> 100 μM) enhances TNFα-induced neutrophil apoptosis, lower concentrations (1-30 μM) completely blocks TNFα-stimulated apoptosis in human neutrophils. [4] Z-VAD-FMK (10 mM) inhibits apoptosis in anterior stromal keratocytes. Z-VAD-FMK (10 mM) inhibits apoptosis in anterior stromal keratocytes detected with the TUNEL assay. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
GC1a NFHGPVRCeG:ydH;zbZMhSXO|YYm= NWnhR2MyPTEQvF2= MkCzNlRp NVfie41bcW6maXPheIV{KGFicILveIVkfGm4ZTDl[oZm[3RiYXfhbY5{fCCndH;wc5Nq\GV? MnrxNlYyPjlyN{W=
HGL5 NXi1UWxISXCxcITvd4l{KEG|c3H5 MW[1NO69VQ>? MnPWNlRp MVTpcoRq[2G2ZYOgZUBxem:2ZXP0bZZmKGWoZnXjeEBi\2GrboP0JIV1d3Cxc3nk[S=> MVeyOlE3QTB5NR?=
HepG2 NFjpOGlCeG:ydH;zbZMhSXO|YYm= MknkNlDPxE1? M4Kzb|Fp MonjZZR1\W63YYTl[EB1cGViYYDvdJRwfGmlIHnu[JVkfGmxbjDv[kBKUUlvMUFCpC=> NXfJfotJOjZzNkS3PVU>
BEL-7402 Ml;BRZBweHSxc3nzJGF{e2G7 NXvm[HZQOjEQvF2= NHm0UmQycA>? MnnmZZR1\W63YYTl[EB1cGViYYDvdJRwfGmlIHnu[JVkfGmxbjDv[kBKUUlvMUFCpC=> NX;0PGJ2OjZzNkS3PVU>
CEF NWH5T29bU2mwYYPlJGF{e2G7 NGftNosxNDN|LE[3MFExOM7:TR?= MoLDNVVucW5? NIK4fY1ld3ewLYLl[5Vt[XSnczDQVkBmdnq7bXWgZYN1cX[rdImgeI8hPDExvJWgZZQhOTByzszN M4TEW|I3OTB{M{O5
SP2/0 Mo\zRZBweHSxc3nzJGF{e2G7 M4e0flExOM7:TR?= MoS2NYg> NX;Cc|I3TE2VTx?= MkfsZoxw[2u|IITo[UBieG:ydH;zbZMhd2ZiU2CyM|Ah[2WubIO= NIn1OlIzPjB5NEezNi=>
HUVEC-2c NFX0U3hCeG:ydH;zbZMhSXO|YYm= M3vzOVUx|ryP M1zGflZp MlnV[IVkemWjc3XkJJRp\SCxeD3MSGwucW6mdXPl[EBifXSxcHjh[5k> M2riOlI3ODJzN{K5
U1 NGrwPHlCeG:ydH;zbZMhSXO|YYm= M{fWVFAuOTByzszN MoruNog> NGjHVJhz\WS3Y3XzJIRzfWdvaX7keYNm\CCjcH;weI9{cXNiYX7kJJN2[nOncYXlcpQhUEmYLUGgdoVxdGmlYYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MXSyOVk5ODl2Mh?=
ACH-2 Moe2RZBweHSxc3nzJGF{e2G7 MkjnNE0zODEQvF2= MYKybC=> MXry[YR2[2W|IHTyeYcucW6mdXPl[EBieG:ydH;zbZMh[W6mIIP1ZpNmeXWnboSgTGlXNTFicnXwcIlk[XSrb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MVOyOVk5ODl2Mh?=
U1 M4TK[WtqdmG|ZTDBd5NigQ>? MnfUNVAx|ryP NW\2[5JVOmh? Mo\NbY5pcWKrdIOgZ4F{eGG|ZT2z M2j5UlI2QThyOUSy
A549/V16 NXjn[3dOSXCxcITvd4l{KEG|c3H5 NYXaTZBKPTEQvF2= NIHJR24ycA>? M{PsPJJmeHKnc4Pld{BVTy:WTT3pcoR2[2WmIHHwc5B1d3Orcx?= NECyO3gzPTl2NkCzNy=>
SGN NXq4VJI1SXCxcITvd4l{KEG|c3H5 NGnJ[HozOG2P NXLOPFFEPDiq M3\qWYhieyCwbzDpcoZtfWWwY3Wgc44hSUmILDDjZYxx[WmwIHX4dJJme3Orb36gc5Ih[2WubDDhdI9xfG:|aYO= M3\yUlI2QDd2NkOz
HCT116  NXXwO2s4SXCxcITvd4l{KEG|c3H5 M{HoblUx|ryP MV[ybC=> MkTabY5pcWKrdIOgeIhmKGOnbHyg[IVifGhiaX7keYNm\CCkeTDESHZR MUeyOVg3QDhzOB?=
DTK-SME M4fqbWFxd3C2b4Ppd{BCe3OjeR?= NV;IcnRDPTEQvF2= NInTXJQzcA>? M2rrb2ROW09? MoS0dIFzfGmjbHz5JIlvcGmkaYTzJJRp\SCjcH;weI9{cXNiaX7keYNm\CCkeTDieZBqfmGlYXnu[S=> NFXQSGkzPTh2M{i5Oy=>
HL-60 M3;DPGFxd3C2b4Ppd{BCe3OjeR?= NVzDO|diPTEQvF2= M3nweFQ5cA>? NHPOPHFz\WS3Y3XzJINmdGxiZHXheIgh[2G3c3XkJIJ6KFONST3JTUB1emWjdH3lcpTDqA>? MnTZNlU5OjRyNEO=
U937 NGXBPJZCeG:ydH;zbZMhSXO|YYm= NGK5cWI2OM7:TR?= NVLjUlh4PDiq NEL5e2Jz\WS3Y3XzJINmdGxiZHXheIgh[2G3c3XkJIJ6KFONST3JTUB1emWjdH3lcpTDqA>? M3jycVI2QDJ2MESz
A549 NWnlfVhUSXCxcITvd4l{KEG|c3H5 M2j0VlIxKM7:TR?= Ml23NlRp Mm\sdoVlfWOnczDj[YxtKGSnYYToJINifXOnZDDifUBJTkOSIITy[YF1dWWwdB?= M4m0bVI2Pzl2MUS5
HeLa NYDyWpZjSXCxcITvd4l{KEG|c3H5 MXWxNO69VQ>? MXO0PIg> NV;XTWN4\GWlbHnu[ZMhfGinIILheIUhd2ZiYYDvdJRwe2m|IHTyZY1ifGmlYXzsfS=> Mor3NlU4PzJ3NEW=
SGC-7901 NIf0OXJCeG:ydH;zbZMhSXO|YYm= NH36boIzOMLizszN MVyxbC=> NEfsV3BqdmirYnn0d{B1cGViY3XscEBl\WG2aDDpcoR2[2WmIHL5JI95[WyrcHzheIlv MV:yOVc3PzB5Nh?=
MCF-7 MlLaRZBweHSxc3nzJGF{e2G7 MlzYNVDPxE1? NVfaVZRPOmh? MkftbY5pcWKrdIOgeIhmKGOnbHyg[IVifGhiaX7keYNm\CCkeTCzRi=> MXOyOVczOjFzNB?=
A549 M4SzPWFxd3C2b4Ppd{BCe3OjeR?= MoXyNVAh|ryP M1Hld|I1cA>? M3HldWROW09? NFfLbGFxem:vb4Tld{BJSkNvdILlZZRm\CCDNUS5JINmdGxic4Xyeol3[WxiJjDheJRmdnWjdHXzJJRp\SClbHXheoVlKFCDUmCg[ZhxemW|c3nvci=> NGrUcWwzPTZ6M{W2PC=>
U87 NF\TRWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7xOVDPxE1? NXSx[I9UOWh? M4LubZJm[2:4ZYLzJINmdGxiZ4Lve5RpKG[{b32gWG1bKHS{ZXH0cYVvfA>? NYHlPVQ5OjV4OEG2Olg>
Neocortical Neuron NFjp[GNP\XW{b4TvfIlkcXS7IFHzd4F6 MWixNFDPxE1? NH;UdnMycA>? M1nGToFvfGGpb37pfoV{KEixaXHtbYRmKEFvSX7keYNm\CCQZYXyc5RwgGmlaYT5 Mm\PNlU3PzVyMEG=
Primary human placental cytotrophoblasts M{fOeGFxd3C2b4Ppd{BCe3OjeR?= NHTCXlg{OM7:TR?= MknFNlRp M3z5R2ROW09? MYTy[ZZmenOnczD0bIUhcW6qaXLpeIlwdiCxZjCxNe6zNUiVREKgZpkhfHKrY3zvd4FvyqB? MorONlU3PDJ3OUK=
MM M3X0TGFxd3C2b4Ppd{BCe3OjeR?= MkS2OVDPxE1? MkjaNlBucW5? MofJdIFzfGy7IHnubIljcXS|IGPIT{1qdmS3Y3XkJEBk\WyuIHTlZZRp MoHPNlU2OzByOUi=
DLD1 Mnz0RZBweHSxc3nzJGF{e2G7 NULEUWtoOjEEoN88US=> NYTy[4NqOWh? NELWSmRx[XK2bImgdoV3\XK|ZYOgZ4VtdCCjcH;weI9{cXNiY3H1d4VlKGK7IGfTVFE> MmDrNlU2OjR{NE[=
MDA-MB-231 MmHpR5l1d3SxeHnjbZR6KEG|c3H5 MXyxNO69VQ>? MXGxbC=> NXPyUoJJ[XWpbXXueJMh[2WubDDk[YF1cCCjZoTldkBEUFWDIITy[YF1dWWwdB?= Mnm5NlU2OjF3MEG=
MKN28 MnnnRZBweHSxc3nzJGF{e2G7 M{CxSlEx|ryP NV:3dpZWOzCvaX6= NELHdFFFVVOR Mn7obY5pcWKrdIOgWG5HNc7zIIDseZMhS0i[LXnu[JVk\WRiYYDvdJRwe2m| NWfBRo5{OjV3MUO5OlA>
HL-60 MVjDfZRwfG:6aXPpeJkhSXO|YYm= MXKxNFDPxE1? Mo\RNYg> NFPu[2hFVVOR M3:zS:KhcW2ycn;2[ZMhfmmjYnnsbZR6KG:oIGTDUmF{NXS{ZXH0[YQh[2WubIO= MmfPNlU2ODJ7M{K=
AGS NULIdGZMSXCxcITvd4l{KEG|c3H5 NILpdmwyOM7:TR?= MUexbC=> Ml\EdJJmfmWwdIOgZ5Vz[3WvaX6tbY5lfWOnZDDjcIVifmGpZTDv[kBk[XOyYYPlMVMtKC16LDDhcoQhNTlicILveIVqdnN? MnvqNlU1QTJ{MUS=
A549  MUTBdI9xfG:|aYOgRZN{[Xl? MUWxNO69VQ>? MXOyOIg> MW\icI9kc3NiRF3BV{1qdmS3Y3XkJINt\WG4YXflJI9nKGOjc4Dhd4UuOyCjbnSgVGFTWCCjbnSgZZBweHSxdHnjJINmdGxiZHXheIg> NXTBclZSOjV2M{S5PFk>
INS-1 MnTXRZBweHSxc3nzJGF{e2G7 NUO0Z|J3PTEQvF2= MknlOog> NYnZZpBsTE2VTx?= Mle1[IVkemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJIViemy7IHHwc5B1d3SrYzDj[Yxte8Li NVXB[2d6OjV2M{C4PVc>
Primary hepatocytes  NY\QRpNbSXCxcITvd4l{KEG|c3H5 NYPicGdxPTEQvF2= M4WyfVE5cA>? NYrTSJBWcW6qaXLpeJMh[XCxcITvd4l{KG:oIHjldIF1d2O7dHXzJIlv\HWlZXSgZpkhSWO2IFSgZY5lKFSQRj5OtS=> MoHVNlU1ODd3M{i=
L929-A  MV\DfZRwfG:6aXPpeJkhSXO|YYm= M4H1WVIxyqEQvF2= M3njO|I1cA>? NHXkeWZqdmirYnn0d{BVVkcQsT3pcoR2[2WmIHPlcIwh\GWjdHi= NETqRoEzPTN7OEW0NC=>
L929-N NUDrOpkxS3m2b4TvfIlkcXS7IFHzd4F6 MnvMNlDDqM7:TR?= MmH3NlRp MX\lcohidmOnczDk[YF1cCC4aXGgZZV1d2O{aX7lJHRPTs7zIIDyc4R2[3Srb36= NH3PbYEzPTN7OEW0NC=>
Cytotoxicity Assay MlvrR4VtdCCYaXHibYxqfHliQYPzZZk> MUmyNO69VQ>? NI\m[Vk1QGh? Ml3LdJJmfmWwdDDNTG1FNWmwZIXj[YQh[2WubDDk[YF1cA>? MX[yOVM6OjFzNh?=
COS7 MVXLbY5ie2ViQYPzZZk> MkPHNVDPxE1? MXGyOIg> Mle5bY5kemWjc3XzJINie3Cjc3WgN{84KGGldHn2bZRq\XN? MmrCNlU{QDRyMkW=
COS7 MWXBdI9xfG:|aYOgRZN{[Xl? NFPsVGMyOM7:TR?= NUDWb2t{PDiq MVnwZZJ1cWGubImgdJJmfmWwdHXkJGZEOTBzLXnu[JVk\WRiY3XscEBl\WG2aB?= NE[yfZMzPTN6NECyOS=>
A375 MV3BdI9xfG:|aYOgRZN{[Xl? NXzXZo5mOzEQvF2= MVuybC=> Mm[wdJJmfmWwdIOgeIhmKGS{dXetbY5lfWOnZDDQRXJRKGOuZXH2ZYdm NF[wVI0zPTN5NkGxOS=>
A549 M1XT[WFxd3C2b4Ppd{BCe3OjeR?= M1rkTVUx|ryP NWDKW2R7OjSq MojTdoV3\XK|ZYOgdoljd3OxbXWgZolw\2WwZYPpd{BidmRiYYDvdJRwe2m|IHPheZNm\CCkeTCgR4hqcm:wZ3Thci=> M1\TTlI2OzR7N{ix
A549 NX\McGJ6SXCxcITvd4l{KEG|c3H5 M{XYO|IvPS1{Nd88US=> NWj5TZJlOWh? Mlm3[IVkemWjc3XzJJRp\SCyb4D1cIF1cW:wIH;mJIFxd3C2b4TpZ{Bk\WyuczDk[ZBmdmRib36gZ49v[2WwdILheIlwdnN? NF\sXJEzPTN2MkSyOy=>
 NBL-W-S  NGDUZmtCeG:ydH;zbZMhSXO|YYm= NV;yO3c5PTEQvF2= NGTGbFIycA>? M4GxdIZ2dGy7IILld4N2\XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgS2FPXC14MTD0doVifG2nboS= NHTsbIkzPTN{M{KyNi=>
Caki-1  MVPBdI9xfG:|aYOgRZN{[Xl? MWi0NO69VQ>? MXi0PIg> NVXIc2hsemWmdXPld{B1cGViboXtZoVzKG:oIFHucoV5cW5iVj3wc5NqfGm4ZTDj[Yxtew>? MV:yOVI4QTF7MR?=
769-P NGnoN2tCeG:ydH;zbZMhSXO|YYm= NIH3TII1OM7:TR?= MYm0PIg> MmDHdoVlfWOnczD0bIUhdnWvYnXyJI9nKEGwbnX4bY4hXi2yb4PpeIl3\SClZXzsdy=> NYOxclVpOjV{N{mxPVE>
H9c2 NV3SWGR2SXCxcITvd4l{KEG|c3H5 NW\aOXVZPTEQvF2= MUCxbC=> NGXvbHJqdmirYnn0d{BFV1hvaX7keYNm\CClYYPwZZNmKDNiYXP0bZZifGmxbjDieZQhdm:2IITo[UBtd3O|IH;mJINmdGy| NHTm[FkzPTJ6M{ixPS=>
K562 NUDYV|IzSXCxcITvd4l{KEG|c3H5 NHi0NFM2OM7:TR?= MYG0bC=> Ml3GbY5pcWKrdIOgToFkNUFvaX7keYNm\CClZXzsJIFxd3C2b4Ppdy=> M2jGV|I2OjRzNkG5
L929 MUDBdI9xfG:|aYOgRZN{[Xl? MkL2NVDPxE1? NVvXOJNMPmh? M4\XVIlv\HWlZYOgcoVkem:ydH;zbZMhf2m2aDDUUmY> MU[yOVE6PTZ4MB?=
A549 NVPNNnZRSXCxcITvd4l{KEG|c3H5 MYWxNO69VQ>? NUDhSYExO2h? MWjy[YR2[2W|IHPlcIwh[XCxcITvd4l{KGOjdYPl[EBjgSCSUWG= M3XLdFI2OTZzNkm5
MCF-7 NVjuXJJDSXCxcITvd4l{KEG|c3H5 MnmyNlDPxE1? NUnDWW82Omh? MUjk[YNz\WG|ZYOgT2RTNXOrUl7BMYlv\HWlZXSgZZBweHSxc3nz M3X2bFI2OTh{MkSw
OS NWPMT5A5SXCxcITvd4l{KEG|c3H5 NVniWVRwOjBxNEFOwG0> NUSyRmN1PzKq NXLLW2FMcW6qaXLpeJMhV1NiY3XscEB3cWGkaXzpeJkhemWmdXP0bY9vKGK7IFO2JINmemGvaXTl MXqyOVE2OjN7OR?=
HUVECs NW\RUHF4SXCxcITvd4l{KEG|c3H5 NEfFbFQyOM7:TR?= MkT4Nog> NUnNfJdbyqCrbnjpZol1eyCjcH;weI9{cXNiYX7kJIZi[2muaYTheIV{KGG3dH;wbIFogSCrbjDESW5XOi2rbn\lZ5Rm\CCKVW\FR5M> NGP0R3EzPTF|OEewNy=>
EA.hy926 M{PySmFxd3C2b4Ppd{BCe3OjeR?= MmPCNVDPxE1? NVHE[mZxOmh? MXNCpIlvcGmkaYTzJIFxd3C2b4Ppd{BidmRiZnHjbYxqfGG2ZYOgZZV1d3CqYXf5JIlvKESHTm[yMYlv\mWldHXkJGVCNmi7OUK2 MnzENlUyOzh5MEO=
Ebs MmT1RZBweHSxc3nzJGF{e2G7 M{[4d|ExNTFyMN88US=> MmryNlRp MV5CpG1OXFNiZ3Xu[ZJifGmxbjDyZZRmKGSnY4LlZZNm\CCjczD0bIUh[2:wY3XueJJifGmxbjDv[kB7NV[DRD7mcYshcW6lcnXhd4Vl NUnVeJFmOjVzM{S4NVc>
Jurkat NHHYd3dCeG:ydH;zbZMhSXO|YYm= MUWyNO69VQ>? MWqyOIg> NVnXR2p7TE2VTx?= MWrwZZJ1cWGubImgbY5pcWKrdDDj[YxtKGSnYYToJI9nKEq3cnvheEBk\WyuczDpcoR2[2WmIHL5JFExODV6LV[0JINwdWKrbnXkJJdqfGhiVmDBxsA> MVSyOVEzODd{Mx?=
K562 MW\BdI9xfG:|aYOgRZN{[Xl? NI\1S3gxNjFvMd88US=> M{Ppd|Fp NHLNSohqdmirYnn0d{BkdGWjdnHn[UBw\iCKU2C5NEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MYeyOVEyQTF6OB?=
IMR-32 NVjldmZYSXCxcITvd4l{KEG|c3H5 MoPxOFDDqM7:TdMg NW\z[XdYOmh? Mor5[IVkemWjc3WgbY4h[XCxcITveIlkKGOnbHzzJINwdXCjcnXkJJRwKFRvMjD0c5hqdg>? MnW4NlUxQDR5NUW=
RPMI 8226 MnPnRZBweHSxc3nzJGF{e2G7 MnfINVAx|ryP NG\kWYYycA>? MYnhcI1we3RiY3;tdIxmfGWueTDicI9kc3NiY3XscEBl\WG2aDDjZZV{\WRiYomgcoVkem:|dHH0bY4uOQ>? NWjTWItNOjVyM{e4OVE>
U266  NHrnXINCeG:ydH;zbZMhSXO|YYm= NYnqTppEOTByzszN M{\VZlFp NG\qfItx[XK2aXHscJkh[myxY3vzJINmdGxiZHXheIgh[2G3c3XkJIJ6KG6nY4Lvd5RifGmwLUG= Ml\FNlUxOzd6NUG=
H929  MXnBdI9xfG:|aYOgRZN{[Xl? NX3ldWV6OTByzszN NV7ndJd6OWh? M{jrT5BienSrYXzsfUBjdG:la4OgZ4VtdCCmZXH0bEBk[XW|ZXSgZpkhdmWlcn;zeIF1cW5vMR?= NGDXcmozPTB|N{i1NS=>
MM.1S  M1zUOGFxd3C2b4Ppd{BCe3OjeR?= MmfLNVAx|ryP M2\HfFFp M12wSoVn\mmlaXXueIx6KHC{ZY\lcpR{KHOxcnHm[Y5q[i2rbnT1Z4VlKGOnbHyg[IVifGhiY3;tZolv\SC5aYToJI5m[3Kxc4TheIlvNTF? MkP6NlUxOzd6NUG=
C6 MlvVRZBweHSxc3nzJGF{e2G7 MUe1NO69VQ>? NVvaXopHPDiq NEnWdppxemW4ZX70d{B1cGVibH;zd{Bw\iClZXzsJJZq[WKrbHn0fUBk[XW|ZXSgZpkheHKnZ37lco9td26n NHv6fIwzPTBzM{S3PS=>
AGS M3ryOmFxd3C2b4Ppd{BCe3OjeR?= NFPjXGQ2OM7:TR?= MVKyOIg> M3rSUYFjd2yrc3jzJO6zNWyjcHHjbI9v\S2rbnT1Z4VlKGOnbHyg[IVifGhiYX7kJIlvcGmkaYTl[EBoem:5dHi= MVGyOVAxQTZ7OB?=
HeLa  M3v6WGFxd3C2b4Ppd{BCe3OjeR?= M1rjRVQx|ryP M{LCRVI1cA>? NX\Ncot7cW6qaXLpeJMhfGinIHnuZ5Jm[XOnZDDhdI9xfG:|aYOgbY5lfWOnZDDifUB{cVKQRkGyNS=> NFzIOZozPDl{OE[4OS=>
THP-1  NYWzNVV{SXCxcITvd4l{KEG|c3H5 NUH4ellHOTEQvF2= M1vTeFFp NUX2ZXE5emWmdXPld{BieG:ydH;zbZMhcW6mdXPl[EBjgSCDTFGtV2RVyqB? M33WR|I1QTJ|NkWz
P815  MYrBdI9xfG:|aYOgRZN{[Xl? MoLUNVAxKML3TR?= MVSxNog> M{XzXmROW09? MUTpcohq[mm2czD2bZJ2ey2rbnT1Z4VlKGGyb4D0c5Nqew>? MVeyOFkzOzJ5Mx?=
HCT116 M{K4TWFxd3C2b4Ppd{BCe3OjeR?= M1HhflIx|ryP NEjHdoMzPGh? Mo\mZYJzd2ejdHXzJI9nKFSTLXnu[JVk\WRiYYDvdJRwe2l? M{\OU|I1QDlyNES5
SW1116  M1;MVmFxd3C2b4Ppd{BCe3OjeR?= M{nLRlExKML3TR?= NVnMeFVYOWh? MkHKSG1UVw>? NUHEemVXemW|dILhbY5{KGOnbHygZZBweHSxc3nzJIlv\HWlZXSgZpkh\2WoaYTpcoljKHCudYOg[IVkcXSjYnnu[S=> NXjhdYc5OjR6N{SyPFY>
LOVO NVvBToVFSXCxcITvd4l{KEG|c3H5 MV:xNEDDvU1? MY[xbC=> MofUSG1UVw>? NV7TPHplemW|dILhbY5{KGOnbHygZZBweHSxc3nzJIlv\HWlZXSgZpkh\2WoaYTpcoljKHCudYOg[IVkcXSjYnnu[S=> NIjLZYMzPDh5NEK4Oi=>
SNU449  MoPrRZBweHSxc3nzJGF{e2G7 MVmyNO69VQ>? NH;oXm01QGh? Ml;MSG1UVw>? MYXk[YNz\WG|ZYOgcYlTNTR3MT3pcoR2[2WmIHHwc5B1d3SrYx?= M1vnNVI1QDRzNkO4
Caco-2 NE\wWJFCeG:ydH;zbZMhSXO|YYm= NEO4WIw1OOLCid88US=> M1zKOlRp M{nDZZBz\X[nboTzJHNVNTdvaX7keYNm\CCcTz2xJINp[W6pZYOgZY5lKFSHUjDkdo9x Ml7iNlQ5OjJzOEO=
macrophage M2rTbWNmdGxiVnnhZoltcXS7IFHzd4F6 NH\hbW0xNTJyMN88US=> MVmyOIg> MoLsbY5lfWOnczDUUmYuKGGwZDDSbZA{NWSncHXu[IVvfCCwZXPyc5B1d3OrczDpckBu[WO{b4DoZYdm MWmyOFc6QTV4NR?=
AGS  NX[yU3hSSXCxcITvd4l{KEG|c3H5 MkHtNlDPxE1? M3PjUVEzcA>? MX7EUXNQ M4OzUpJm\HWlZYOgeIhmKGmwZIXjeIlwdiCxZjDhdI9xfG:|aYOgbY4hemW|cH;ud4UhfG9idHjlJGV1V0GlIH\yZYN1cW:wIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MUWyOFc5QTdyMx?=
LCC9  MYDD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NETEUZYyODEQvF2= NIjHU3g2\A>? NV;KTHpy[myxY3vzJINmdGxiZHXheIghcW6mdXPl[EBjgSClb33ibY5ifGmxbjDMNVch[W6mIHPocI9zd3G3aX7l NG\tWlkzPDd6NUK1Oi=>
U937  NFvRZWlv\WO{b4D0c5NqeyCDc4PhfS=> M4i3VFExyqEQvF2= NIHveIM{OMLibXnu NGDWd3NqdmS3Y3XzJI5m[3KxcITvd4l{KGOxbXLpcoUhf2m2aDDUUmY> NHXVOowzPDd5M{e1Oi=>
T cell NV;qOXJ6S2WubDDwdo9tcW[ncnH0bY9vKGG|c3H5 MnH1NE0yODEQvF2= MVO3Nog> M4XRWWlEPTB;N{Cg{txONCCrbnjpZol1eyCjboTpMWNFOy2rbnT1Z4VlKFRiY3XscEBxem:uaX\ldoF1cW:wIHnuJHBDVUO| NVS1c2lLOjR5Nki3NFc>
HeLa  MkHaRZBweHSxc3nzJGF{e2G7 NYDwRZlwPTEQvF2= NYTjdHpHPzKq NWLJT2syTE2VTx?= NX7CTpNieHKndnXueJMh[XCxcITvd4l{KGmwZIXj[YQh[nliY3;tdI92dmS|wrCx5qCUPQ>? M1O2OlI1PzV2N{i2
HeLa  NYr5cI1iSXCxcITvd4l{KEG|c3H5 NYDHU3prOTByzszN MnvlNlRp NV\aU4s3e3WycILld5NmeyC{YYTlJI9nKGOnbHyg[IVifGhiaX7keYNm\CCkeTDveoVz\XiycnXzd4lwdiCxZjDHOVlUKG:{IFe3NXIheDF3MHfseYVlyqB? NVTLWZlqOjR5MkK0Olg>
IEC-6  NWHabYxHSXCxcITvd4l{KEG|c3H5 MYKxNO69VQ>? M2rTd|I1cA>? MlnPdJJmfmWwdIOgWINlSS2rbnT1Z4VlKGOjc4Dhd4UuOyClbHXheoFo\SCjbnSg{tIu[2G2ZX7pckBl\We{YXTheIlwdg>? M4\KdVI1PzFzNUex
HCT116 Mnm2RZBweHSxc3nzJGF{e2G7 M{H4RlIx|ryP NIjJN|gzPGh? MU\pcohq[mm2czD0bIUh[2WubDDhdI9xfG:2aXOgbY5lfWOnZDDifUB[VFR{MEW= M4i0OVI1PzF|OEGy
L02 NUfPVYhzSXCxcITvd4l{KEG|c3H5 MXKyNO69VQ>? NInJfFIycA>? M1myN5Bz\X[nboTzJJRp\SClZXzsJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KE2HSGC= NVHxNZVyOjR5ME[0OlE>
A375 NGr4[lBCeG:ydH;zbZMhSXO|YYm= NEW0c|kzOM7:TR?= MmXYNlRp M2O3dJJmfmW{c3XzJIRq[2m2cnnuc45mKEJvaX7keYNm\CCjcH;weI9{cXN? MVuyOFY6QTFzMR?=
HDPC MUDBdI9xfG:|aYOgRZN{[Xl? NFK4SVA2OML3TR?= NH3kXlczPGh? M2P6[4lvcGmkaYTzJG5QNWmwZIXj[YQh[XCxcITvd4l{ NVTx[JhzOjR4M{S1PVM>
A549 NWfmZ4E3SXCxcITvd4l{KEG|c3H5 NXrzTYRKPTEEtV2= M{\pWFJp M{jUXmROW09? NV3Le4tbeHKndnXueJMhfGinIHj5dI9lcXCub3nkJGRPSSClb370[Y51KHCqYYPlJIlv\HWlZXSgZpkh[2WyaHHsc4Npem:vaX6= NXLGN3FSOjR3OEixN|U>
 BV-2 M4HWOGFxd3C2b4Ppd{BCe3OjeR?= Ml\RNlDPxE1? M2XQZ|Jp MnzFd5VxeHKnc4Pld{BWXi2rbnT1Z4VlKGOqcn;tZZRqdiCneITyeZNqd25iYX7kJIRqdGG2aX;uJI9nKHSqZTDueYNt\WG{IHXueoVtd3Cn NHPkNZYzPDV3OEGxPC=>
HT-29  NXnVNnA6SXCxcITvd4l{KEG|c3H5 NUPzVIUzPTEQvF2= NXS1bWdEPDiq MVXicI9kc3NidHjlJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KGujZX3w[oVzd2x? Ml7TNlQ2PDlzN{W=
A549 MkLtRZBweHSxc3nzJGF{e2G7 M2O4TlXPxE1? MWiyOIg> Mn7kd5VxeHKnc4Pld{A3\cLiKFLLNVAxPDBrLXnu[JVk\WRiYYDvdJRwe2m|wrC= NU\Ed4o6OjR3Mkm4O|E>
MIA-PaCa-2 NHexenhCeG:ydH;zbZMhSXO|YYm= MXSyOIg> NUWwPXVQ[myxY3vzJINt\WG4YXflJI9nKGOjc4Dhd4UuOyCrbnT1Z4VlKGK7IHLveIghSS12NEO2OVQh[W6mIIDhZ4xqfGG6ZXy= NEPtbnUzPDVzMEm5Ni=>
Caki-1 NITNe3ZCeG:ydH;zbZMhSXO|YYm= MWGyNO69VQ>? M1T4O|Fp MWjpcohq[mm2czDTR3AucW6mdXPl[EBieG:ydH;zbZM> M4Tpb|I1PTB2Nkix
CLL NHHuboZCeG:ydH;zbZMhSXO|YYm= NI\pb3gzPc7:TR?= NFTGOZAycA>? NYXzW45seGG{dHnhcIx6KGKub3Prd{BOVE5{MkO4MYlv\HWlZXSgZ4VtdCCjcH;weI9{cXN? NHjubIgzPDR4N{[zOC=>
SGC-7901 MUTBdI9xfG:|aYOgRZN{[Xl? NUnrPHlbOTEQvF2= M{jpNlI1cA>? MYrwdo9ud3SnczD0bIUhS0eLST3pcohq[mm2ZXSgZ4VtdCCpcn;3eIghcW5iU1fDMVc6ODFiY3XscJM> MUWyOFQ2PDR6OB?=
k1735 NWrEdZJ2SXCxcITvd4l{KEG|c3H5 MYKyNQKBkc7:bR?= NUO1VG1LPGh? Ml7ibY5pcWKrdIRCpHNidG2xbnXscIEucW6mdXPl[EBieG:ydH;zbZM> MWGyOFQ2OTFzNh?=
HaCaT  NEHjWINCeG:ydH;zbZMhSXO|YYm= NILweFgyODEQvF2= NFTpNGwycA>? M3PGeoJtfW62czDVWmIucW6mdXPl[EBieG:ydH;zbZMhcW5iSHHDZXQh[2WubIO= MYSyOFM2Pjl7Nx?=
podocytes M17GXGFxd3C2b4Ppd{BCe3OjeR?= NXjlbnNxOjByzszN M{TKcVZp M2PTPYlvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KDNuND3ES2U> NWTJOWlOOjR|M{e3O|c>
 KB NWPNW3JqSXCxcITvd4l{KEG|c3H5 MlfWOVDPxE1? MXyyOIg> MlXPbY5pcWKrdIOgUIlkdy2DLXnu[JVk\WRiY3HzdIF{\S1|IHHu[EBRSVKSIHHjeIl3[XSrb36= MXiyOFM{PzR7Mh?=
 HepG2  M1fNZmFxd3C2b4Ppd{BCe3OjeR?= M2DBTlEx|ryP NETnUJIzPGh? NXn2Zm13emWmdXPld{B3cW2nboTpckBkdGWjdnHn[UBk[XW|ZXSgZpkhVFCV MmDWNlQ{OjV6MU[=
fetal rat lung fibroblasts  NGTEN3dMcW6jc3WgRZN{[Xl? NE\IdXI5OM7:TdMg MXOxbC=> Mn[1bY5pcWKrdIOgR4F{eGG|ZT2zJIFkfGm4aYT5xsA> NVK5eIp7OjR|MUSxN|U>
PDL fibroblasts NGXjbo5McW6jc3WgRZN{[Xl? M4fnZlgx|ryPwrC= NILpNngycA>? NYXLW3d[cW6qaXLpeJMhS2G|cHHz[U0{KGGldHn2bZR6yqB? MXOyOFMyPDF|NR?=
MB49 MoWxRZBweHSxc3nzJGF{e2G7 M1nKO|Ix|ryP NXXQb|BrOWh? MXfy[ZZmenOnczDDUU1qdmS3Y3XkJINmdGxiZHXheIg> MXqyOFI5OjR|Mx?=
5637 MnzIRZBweHSxc3nzJGF{e2G7 NYfTN3pnOjEQvF2= MXKxbC=> NWi5ZWM3emW4ZYLz[ZMhS01vaX7keYNm\CClZXzsJIRm[XSq M2XtSlI1Ojh{NEOz
A549  NEL5XZRCeG:ydH;zbZMhSXO|YYm= NVzuSIFnOTByzszN NV2y[HhqPDiq NF[xdXd{fXCycnXzd4V{KHSqZTDhdI9xfG:|aYOgZ4F2e2WmIHL5JJBqeGW{aX7lxsA> MUmyOFI4OjJyMR?=
MCC-2 NGTmXHNCeG:ydH;zbZMhSXO|YYm= M4fyNFIxKM7:TR?= M1nvT|Zp NFzkNYdFVVOR MlfOZoxw[2u|IHnu[JVk\WRiYomgd5RifXKxc4Dvdolv\SCjcH;weI9{cXNiY3XscEBl\WG2aB?= NVKyVZN[OjR{NkK2OVg>
ADF M{PLb2Fxd3C2b4Ppd{BCe3OjeR?= MXm0NO69VQ>? MmLROog> M4joW4lvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KGOqZX3veIhmemGyeTDwcJV{KFqwQ3yy M1fYcFI1OjJ6MkOy
 U373  NYTic3BqSXCxcITvd4l{KEG|c3H5 NG\pT481OM7:TR?= NVXSPFdxPmh? MWHpcohq[mm2czDhdI9xfG:|aYOgbY5lfWOnZDDifUBkcGWvb4To[ZJieHlicHz1d{BbdkOuMh?= MnXzNlQzOjh{M{K=
RKO-HIPK2i M1LYc2Fxd3C2b4Ppd{BCe3OjeR?= NWC0WWk5PDEQvF2= MojvOog> NFXKUIxqdmirYnn0d{BieG:ydH;zbZMhcW6mdXPl[EBjgSClaHXtc5Rp\XKjcImgdIx2eyCcblPsNi=> M2rJbVI1OjJ6MkOy
HEC-1B M1X4bmFxd3C2b4Ppd{BCe3OjeR?= MXWyNO69VQ>? M4LRXVFp NHfVSFNz\WS3Y3XzJHRRNWmwZIXj[YQh[XCxcITvd4l{yqClYYPwZZNmNTNiYX7kJINie3Cjc3WtPS=> MXOyOFIyOzN3OB?=
4T1 MoDlR4VtdCCYaXHibYxqfHliQYPzZZk> NVX3e|ZpOi53LUGw{txO MVe0bC=> MlGySG1UVw>? NH2wOmFz\XOldXXzJJRp\SCleYTveI95cWOrdImgc4YhPFRzIHPlcIx{KGmwZIXj[YQh[nliU2DEWEBqdiCjIHPvcoNmdnS{YYTpc44h\GWyZX7k[Y51KG2jbn7ldi=> M3u1N|I1OjB4MU[x
OS  NVXNbJdKSXCxcITvd4l{KEG|c3H5 MWKyNO69VQ>? NH;Oc2k1cA>? NHLzO5NqdmirYnn0d{B1cGViY3XscEBl\WG2aDDjZZV{\WRiYomgVGRV NI\4XmwzPDJyNEmzOy=>
RPE NVPmO4lYSXCxcITvd4l{KEG|c3H5 MYCxNFDPxE1? MVi0PIg> MXLwZZJ1cWGubImgbY5pcWKrdIOgeIhmKGOjbIDhbY4uOSCjbnSgMVIh[WO2aY\heIlwdiCjczD3[YxtKGG|IITo[UBk[XOyYYPlJIFkfGm4YYTpc44> M37qTlI1OjB{MEWy
UD29a NFfldHNCeG:ydH;zbZMhSXO|YYm= MorLOVDPxE1? MYCyOIg> MVnpcohq[mm2czD0bIUh[2WubDDk[YF1cCClYYXz[YQh[nliTmXUNy=> NVj0d|Q3OjRzOUC1O|Q>
SH-SY5Y  MnrqRZBweHSxc3nzJGF{e2G7 NWi5[HFQOTEQvF2= NF\QZ4czPGh? Ml;YZZR1\W63YYTld{Bk[XOyYYPlJIFkfGm4YYTpc44h[W6mIHPlcIwh\GWjdHigbY5lfWOnZDDifUBJVkVvMlTH MYiyOFE1PTR4Mx?=
HeLa  NVPReGhDSXCxcITvd4l{KEG|c3H5 NGWwNmYyOC9{MN88US=> NHXmUYUzPGh? MoDNbY5pcWKrdIOgeIhmKGGldHn2bZR6KG:oIITo[UBu[Wqxcnn0fUBw\iC2aHWgcYVu[mW{czDv[kB1cGViY3HzdIF{\S2oYX3pcJk> NGPXUIUzPDF|N{K2Oi=>
SCCVII  NFnaXnlCeG:ydH;zbZMhSXO|YYm= Mmq0NlXPxE1? NYnwS2s6OWh? M1zCUolvcGmkaYTzJJRp\SClZXzsJItqdGyrbnegZYZ1\XJiZHHzZZRqdmmk M4GzU|I1OTJ4NE[0
RAW 264.7 M{fG[mFxd3C2b4Ppd{BCe3OjeR?= MoHjNlDPxE1? MV2xPIg> NHnmVVlqdmO{ZXHz[ZMhVEN|LVnJM:6zNWGldHnuJJJifGmxIHPvcZBiemWmIITvJGVEXFZvTV;TJJRz\WG2bXXueEBwdmy7 MXyyOFEyPjdyNx?=
A549  NHW0UXVCeG:ydH;zbZMhSXO|YYm= M1XHV|IvPc7:TR?= MYWyOIg> MXTk[YNz\WG|ZYOgc5Jq\G:waX6tbY5lfWOnZDDheZRweGijZ4mgZZMhf2WubDDhcoQhVG:|czDv[kDPnM,KbTDhcJNwKG:lY4XydoVlKGS3cnnu[{BifXSxcHjh[4lkKHC{b3Pld5M> MoC2NlQyODJ3MkK=
UM-SCC-10A  NWSyXI5OSXCxcITvd4l{KEG|c3H5 M{\kSVUxyrWP MVyybC=> Mn\KdoVlfWOnczDhdI9xfG:|aYOgbY5lfWOnZDDifUBpcWeqLXTvd4UhcXOxYXzhcpRwdGGldH;u[S=> M2rUTFI1ODl6N{Wz
BGC-823 NHnxcI9CeG:ydH;zbZMhSXO|YYm= MUexNEDPxE1? NWXJeWZyOjSq NYfRZVJIemWmdXPld{B1\XS{YX7kdolv\S2rbnT1Z4VlKGGyb4D0c5Nqe8Li NFXafZMzPDB7OEWxNS=>
Nalm-6  NGL6cHhCeG:ydH;zbZMhSXO|YYm= M13pT|Ix|ryP NInCWIQ1cA>? MX\pcohq[mm2czDjZZNx[XOnLUigZY5lKGOjc4Dhd4UuOyCjY4TpeoF1cW:wIHHu[EBRSVKSLUGgZ4xm[X[jZ3W= MWOyOFA{QTl4Nx?=
KHOS  NHHaO3JCeG:ydH;zbZMhSXO|YYm= M2LYTFQx|ryP MX6yOIg> NXrJb|k3[myxY3vzJJRp\SCrbnPy[YF{\WRiY3zlZZZi\2Vib3[gZ4F{eGG|ZT2zJIFv\CCSQWLQJIlv\HWlZXSgZpkhSkKPRERCpC=> Ml7YNlQxOjV|NkG=
G292 NXWxXFNPSXCxcITvd4l{KEG|c3H5 NXjZOGtqPDEQvF2= MmjDNlRp M{WwNIJtd2OtczD0bIUhcW6lcnXhd4VlKGOuZXH2ZYdmKG:oIHPhd5Bie2VvMzDhcoQhWEGUUDDpcoR2[2WmIHL5JGJDVUR|wrC= MlLmNlQxOjV|NkG=
MG-63 MVrBdI9xfG:|aYOgRZN{[Xl? NXKwWm9PPDEQvF2= MnTKNlRp MYnicI9kc3NidHjlJIlv[3KnYYPl[EBkdGWjdnHn[UBw\iClYYPwZZNmNTNiYX7kJHBCWlBiaX7keYNm\CCkeTDCRm1FO8Li NYXKT5V4OjRyMkWzOlE>
EBV-transformed B cells M4rmPWFxd3C2b4Ppd{BCe3OjeR?= NGHKPGszOM7:TR?= NILve48zcA>? M3\KemROW09? NEfEXmtjdG:la4OgZY51cS2FREiwJIFv\CCjboTpMWNFQDZiYX70bYJw\HlvaX7keYNm\CCjcH;weI9{cXN? NV\vdI1EOjRyMEi2Nlg>
IM-9 B M3fqZmFxd3C2b4Ppd{BCe3OjeR?= NHzkVmMzOM7:TR?= MUmybC=> MV\EUXNQ MoryZoxw[2u|IHHueIkuS0R6MDDhcoQh[W62aT3DSFg3KGGwdHnic4R6NWmwZIXj[YQh[XCxcITvd4l{ MkXONlQxODh4Mki=
CNE1 M{DhTmFxd3C2b4Ppd{BCe3OjeR?= NHrJbHUzOM7:TR?= NX\ndYFIPDiq MlvyZoxw[2u|IFzLMWEucW6mdXPl[EBieG:ydH;zbZM> NYjKXY83OjN7OEWwNlk>
CNE2 MVLBdI9xfG:|aYOgRZN{[Xl? M3\EVVIx|ryP Mn7aOFhp NXvLVVky[myxY3vzJGxMNUFvaX7keYNm\CCjcH;weI9{cXN? MlHaNlM6QDVyMkm=
HL-60 NXjuXFNCSXCxcITvd4l{KEG|c3H5 MnXrOVDDvU1? NYjsVmV6OWh? NVn5R2pxTE2VTx?= M3nYUolvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KEKDMUS1 M4TyRlI{QTR6N{Wx
L929 MmrmRZBweHSxc3nzJGF{e2G7 NUL3cG9ROS5{NfMAl|XDqM7:TdMg MYCyOIg> M2roWYF2\22nboTzJHRPTs7zLXnu[JVk\WRibnXjdo9xfG:|aYOgZY5lKGG3dH;wbIFogQ>? NIn5TWkzOzl2MUe2PS=>
Jurkat MXvD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NXTM[2pQOs7:TR?= M13uOFRp MWPy[ZZmenOnczDndo94fGhiaX7obYJqfGmxbjDhcoQh|rJvY3H0[Y5qdiCmZXPy[YF{\SCkeTDIV{1CW0F? NYjGNo51OjN6OU[wOlE>
RAW264.7  MWXBdI9xfG:|aYOgRZN{[Xl? NXfRfXVZOTBizszN Mkj6NlRp MVHk[YNz\WG|ZYOgeIhmKGGyb4D0c5NqeyCrbnT1Z4VlKGK7IFfB NFXodIQzOzh{MEKwNy=>
A431  M3XvT2tqdmG|ZTDBd5NigQ>? MVK0NO69VQ>? NYLofYRoOmh? MWDicI9kc3NiZnnz[ZRqdi2rbnT1Z4VlKGOuZXH2ZYdmKG:oIHPhd5Bie2W|IHHu[EBRSVKS NH;FR5ozOzhyMEC1PC=>
Jurkat M2iycWNmdGxiVnnhZoltcXS7IFHzd4F6 NFnDXG0zPS1zMEFOwG0> NX3oe2ZzPmh? NXXkfpd4cW6qaXLpeJMhgi2IQT3DUWsucW6mdXPl[EBk\WyuIHTlZZRp MlLaNlM6OzN3M{K=
COS-7  NVjqXI1kTnWwY4Tpc44hSXO|YYm= NVvwOmQyPTEEtV2= M330b|I1cA>? Mn;VZYZn\WO2czD0bIUheHKxY3Xzd4lv\yCxZjDBWG4yeyC5aYToJJBwdHmTIITyZYN1ew>? M2\NSlI{QTN|MkC4
CAL27 NU\mN3E1SXCxcITvd4l{KEG|c3H5 NEPwS4wyOCEQvF2= MXyybC=> MoXEd5VxeHKnc4Pld{BEfXJvTmDzMZJm\HWlZXSgeoli[mmuaYT5JIJ6KHWyIITvJFkxLQ>? NWSwUpF3OjN7MUezPVY>
THP-1  MVPBdI9xfG:|aYOgRZN{[Xl? MUCxNE02OM7:TR?= Mnj6Nog> M4HiUolvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KHS{aYD0c4xq\GV? MYeyN|kxODJ7OR?=
K562 NGTVXVJCeG:ydH;zbZMhSXO|YYm= MUeyNO69VQ>? MYG0PIg> M{nSdYlvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KDRvTWW= MnXtNlM5PzZ6Mk[=
HL-60 NFPWS4lCeG:ydH;zbZMhSXO|YYm= MVyxNFDPxE1? NXzMUY56OjSq M3rYPIlvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KGGkaXX0ZY5mKGSrdHXydIVv\XQEoB?= MkfDNlM5PjV5N{i=
HeLa  MkfZRZBweHSxc3nzJGF{e2G7 NGDp[oUzOM7:TR?= Ml72Nog> NHrrbIhqdmirYnn0d{BFVU2SIHnu[JVk\WRiYYDvdJRwe2m| NH\Hc5YzOzh4M{m2Oi=>
U251 NXXvV415SXCxcITvd4l{KEG|c3H5 MnrqNlDPxE1? NUT1eIVnOjSq MoXabY5pcWKrdIOgZ4F{fGmlaX6gbY5lfWOnZDDHNk9OKHCqYYPlJIFzemW|dDDhcoQh[XCxcITvd4l{ Mmn2NlM5OTZ6MU[=
HL-60 M{jx[GFxd3C2b4Ppd{BCe3OjeR?= NIfa[HU2OML3TR?= MXy0bC=> NVLtS3ZT[myxY3vzJJRp\SClbHXheoFo\SCxZjDjZZNx[XOnLUOsJE06NCCjbnSgVGFTWCCrbnT1Z4VlKGK7IE\z NUjK[3dlOjN6MES3NFY>
Ec-109 MXnBdI9xfG:|aYOgRZN{[Xl? M1nYU|ExKM7:TR?= NV7oV21rPDiq MoTmdoVxemW|c3XzJHBGNW2nZHnheIVlKEWlLUGwPUBk\WyuIHHwc5B1d3Orcx?= NV35XGdYOjN5OEK2OFE>
RKO NYr6OWh3S2WubDDWbYFjcWyrdImgRZN{[Xl? NHPjbIkyOCEQvF2= MX:yOIg> MWXpcohq[mm2czD0bIUh\GWlcnXhd4Uhd2ZiY3XscEB3cWGkaXzpeJkh[2G3c3XkJIJ6KESDQh?= NV;2UpVVOjN5NUiwOlQ>
T98G MXPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NIDOSFgyNTFyMN88US=> MYWyOIg> M{DmSYlueHKxdnXzJINmdGxidnnhZoltcXS7IHPveJJm[XSvZX70JJdqfGhiVGO= NHX5WZczOzd4OUK3OS=>
Jurkat NUDv[oxXS2WubDDWbYFjcWyrdImgRZN{[Xl? M2HOb|ExOC1{MEFOwG0> NIHST5ozPGh? M1;xdolvcGmkaYTzJGhiSTRiaX7keYNmeyCjcH;weI9{cXNiZHXw[Y5l\W62IH;mJINwdmOnboTyZZRqd28EoB?= M3v0fVI{PzN{NEix
Molt-3  NGH0N4tCeG:ydH;zbZMhSXO|YYm= M2npTFUx|ryP NVjDZZBNOmh? MUfy[YR2[2W|IH3lcIF1d26rbj3pcoR2[2WmIHHwc5B1d3Orcx?= NH:we5EzOzd{NUCxNy=>
hMSC12 M3e2TmFxd3C2b4Ppd{BCe3OjeR?= MVOxNFDPxE1? NIXmU2U1\A>? M{Pr[YlvcGmkaYTzJI9{fGWxZ3XubYMh[3WudIXy[U1qdmS3Y3XkJINmdGxiZHXheIgh[W6mIHPhcINq\mmlYYTpc44> MYGyN|Y2Pzh{Mh?=
HM7  M1HKUGFxd3C2b4Ppd{BCe3OjeR?= NE\YT28zOM7:TdMg MYOxbC=> MVvicI9kc3NiYYDpZ5Vt[XKnbjDBJIFk\XSjdHWtbY5lfWOnZDDjZZNx[XOnLUOgZYN1cX[jdHnvckBidmRiUFHSVEBkdGWjdnHn[S=> NV7iV5NWOjN3OEO0NVI>
Hep-2  MkW4RZBweHSxc3nzJGF{e2G7 NFfycowzOM7:TdMg NE\BW20zPGh? M2LvWWROW09? MlfIZYxt\X[rYYTld{B1cGViZHXjdoVie2Vib3[gZ4VtdCC4aXHibYxqfHliaX7keYNm\CCkeTDzbYxq[mmwaX6= MVGyN|U5ODB|Mh?=
HSCs MYTBdI9xfG:|aYOgRZN{[Xl? MkjxOVDPxE1? Ml76NlRp MYLEUXNQ NYjLS5JOcW6qaXLpeJMhdmmub4TpcoljNWmwZIXj[YQhTE6DIHThcYFo\SCrbnTpZ4F1\WRiYomgVGFTWCClbHXheoFo\Q>? M1PTbVI{PDl7OEe0
HL-60  M4fyeGN6fG:2b4jpZ4l1gSCDc4PhfS=> M3zCelIx|ryPwrC= Mlz6NlRp NGXyUW9z\WS3Y3XzJJRp\SCleYTveI95cWNiZX\m[YN1KG:oIFXyfVU> M1O3PFI{PDl2NEiw
HA NYCyNnh{SXCxcITvd4l{KEG|c3H5 M{[4fVUx|ryP NGLTfJkzPGh? NFTJO4l{fXCycnXzd4V{KHSqZTDjcIVifmGpZTDv[kBRSVKSIHHu[EBk[XOyYYPlMVMtKC15LDDhcoQhNTliaX7keYNm\CCkeTDic5J1\XqxbXniM3NCUEF? NVv0UY4xOjN2N{W5OVY>
C666-1 M4jj[GFxd3C2b4Ppd{BCe3OjeR?= NYTVbGNZPTEQvF2= MlrrNlRp M13EZZN2eHC{ZYPz[ZMhfGinIHPs[YF3[WenIH;mJHBCWlBiYX7kJINie3Cjc3WtN{whNTduIHHu[EAuQSCrbnT1Z4VlKGK7IHLvdpRmgm:vaXKvV2FJSQ>? NIPqXpQzOzR5NUm1Oi=>
Hepa1-6 NUT6dmtiSXCxcITvd4l{KEG|c3H5 NEmxTmU2OM7:TR?= M{XaZ|Jp NFTRNItqdmirYnn0d{BkfXKldX3pckBidmRicnXzeoVz[XS{b3ytbY5lfWOnZDDhdI9xfG:|aYO= NXTC[2VLOjN2NE[3OVM>
PLC/PRF/5c NULXNYdVSXCxcITvd4l{KEG|c3H5 M4nPSVUx|ryP M3HyflFp MWrwdoV3\W62czDhdI9xfG:|aYOgeJJq\2encnXkJIJ6KEOLTh?= M{T4elI{PDN6OEK0
HCT116 M4\wS2Fxd3C2b4Ppd{BCe3OjeR?= NInlZpEyODEQvF2= NWjTToRqOS53aB?= NVvQbXU5cW6qaXLpeJMhV3NvaX7keYNm\CClZXzsJIRm[XSq MUmyN|c1PDN3Mx?=
HCEC NHHXXFFHfW6ldHnvckBCe3OjeR?= M{\z[VUx|ryP MUO3Nog> MnvsSG1UVw>? M2noZ5Jme3SxcnXzJI9nKHSqZTDuc5Ju[WxiSFPFR{BxcGWwb4T5dIU> Mmr2NlM4PDJyMUG=
Primary rat cerebral cortical neurons NFjNdo1CeG:ydH;zbZMhSXO|YYm= MXuxNFDPxE1? NXzPbZJ7OWh? NFL4bGpxemW4ZX70d{BE\C2rbnT1Z4VlKGGyb4D0c5NqeyCjbnSgZ4VtdCCmZXH0bC=> NFHHS5MzOzd2MUOxOy=>
MDA-MB-231  MlTwRZBweHSxc3nzJGF{e2G7 NUnpSWhnOjYQvF2= MWWyOIg> MnfnZYJzd2ejdHXzJIN6fG:2b4jpZ4l1gSCjbnSgZ4xm[X[jZ3Wgc4Yh[2G|cHHz[U0{KGGwZDDQRXJRKGmwZIXj[YQh[nliUnez MlPUNlU{Ozd3NES=
NLRP3-Tet-on-MC/9  M3vmRmFxd3C2b4Ppd{BCe3OjeR?= NVrmV4tXOTBvNEFOwG0> NYXpTnhCOTKq NIe4fm1ifHSnboXheIV{KHSqZTDj[YxtKGSnYYToJINifXOnZDDifUBESVCVLXHzd49kcWG2ZXSgUmxTWDNibYX0ZY51eyCrbjD0bIUhXGW2LX;uJJN6e3SnbR?= MWOyN|cxOzN6OR?=
KNS42  MWTBdI9xfG:|aYOgRZN{[Xl? MVm1NO69VQ>? NFPOVHQycA>? NWDudopuemWmdXPld{Bk\WyuIHTlZZRpKGGwZDDjc41xdGW2ZXz5JIFjd2yrc3jl[EBk[XOyYYPlJFMwPyCjY4Tpeol1gSCrbjDy[ZNxd26|ZTD0c{BCSlRvMk[zM|JFTy:vZYTmc5JucW5iY3;tZolv[XSrb36= NXztRVA5OjN4OUGxOFU>
MCF-7  M3iyOGFxd3C2b4Ppd{BCe3OjeR?= NYH0WWhuOjEQvF5CpC=> NETUfXI4Omh? NHjNd2JqdmirYnn0d{BmeXWxbD2gZY5lKDRvT1jUMY1m\GmjdHXkJIFxd3C2b4Ppdy=> NWXoWmNbOjN4N{W2OFM>
hCMEC/D3  MY\BdI9xfG:|aYOgRZN{[Xl? MnXjNlXPxE1? NV76XFNyPzKq MojUdoVlfWOnczDMeJhCKGmwZIXj[YQh[XCxcITvd4l{ NIro[40zOzZ4NUG5PC=>
Jurkat MkjBRZBweHSxc3nzJGF{e2G7 Mlv2NVIvPS13MN88US=> Ml;6NYg> MWfkc5NmKGSncHXu[IVvfGy7IIP1dJBz\XO|ZYOgV3BJNWmwZIXj[YQhWGG{LUSgZ4xm[X[jZ3WsJHBCWlBiY3zlZZZi\2VuIFTORUBnemGpbXXueIF1cW:wLDDhcoQhdG:|czDv[kB3cWGkaXzpeJk> NHm2Z28zOzR2Mkm3Oi=>
CNE-1 M{DXUGFxd3C2b4Ppd{BCe3OjeR?= NIfic3ozOM7:TdMg MVKyOIg> NXzubYZ3cW6qaXLpeJMhWkGGMECxMYlv\HWlZXSgZ4VtdCCmZXH0bC=> MknUNlM1OjZ6NUC=
HONE-1 NH3lZZhCeG:ydH;zbZMhSXO|YYm= Mln0NlDPxE4EoB?= NHrJWXczPGh? NXPTe417cW6qaXLpeJMhWkGGMECxMYlv\HWlZXSgZ4VtdCCmZXH0bC=> MUiyN|QzPjh3MB?=
astrocytes cell MYDBdI9xfG:|aYOgRZN{[Xl? MlTvOFDPxE1? MYe2bC=> NVjuPIhJemWmdXPld{Bm[XKueTDhdI9xfG:|aYOgbY5lfWOnZDDifUB{fGG3cn;zdI9zcW6n Mm\4NlM1OTF5N{i=
U-937 NVz4U3dCSXCxcITvd4l{KEG|c3H5 MVWxNO69VQ>? NX6y[|hlOzCvaX6= M3y0V5Bz\X[nboTzJHRPTi2rbnT1Z4VlKG6nY4LvdJRwe2m| NYLvcnY6OjN2MUC3OFg>
MDA-MB-231 M2XhRmFxd3C2b4Ppd{BCe3OjeR?= M4S1Z|ExOM7:TR?= NHLheGwycA>? MlPpbY5pcWKrdIOgd4Vve2m2aYrheIlwdiC2bzDUVmFKVCC3cH;uJG1VTEhiZH;3ck1z\We3bHH0bY9v NYPwVYxYOjN2MEi0Nlk>
HeLa  NX;YNpBUSXCxcITvd4l{KEG|c3H5 MWWxNFDPxE1? MljxNog> M1LXbIJtd2OtczDKVnMuOTViSX7keYNmeyCDcH;weI91cWNiQ3XscEBF\WG2aB?= MYCyN|M1PDB2NR?=
Ec109 NUfnRXFjSXCxcITvd4l{KEG|c3H5 M1HDbFEx|ryP Mn25Oog> NVT3SpZn[myxY3vzJIFxd3C2b4TpZ{Bkd22kaX7heIlwdiCxZjDUZZQuW22jY163JIFv\CC{YXTpZZRqd25? MnXYNlM{Ozh3Nki=
H460  M{joOWFxd3C2b4Ppd{BCe3OjeR?= NIXZU3gyOM7:TR?= MWe2bC=> MUTicI9kc3NiYYDvdJRwfGmlIHPvcYJqdmG2aX;uJI9nKFSjdD3TcYFkVjdiYX7kJJJi\GmjdHnvci=> MUGyN|M{QDV4OB?=
HeLa  NVXV[ZR5SXCxcITvd4l{KEG|c3H5 NHzXWZc2OM7:TR?= MUSxMlVp NYTyfo5Z[WK{b3fheIV{yqCFaHzhcZllcWFvaX7keYNm\CCjcH;weI9{cXN? MXSyN|MxOzhyNB?=
SK-HEP1 M1LkPWFxd3C2b4Ppd{BCe3OjeR?= MUexNFDPxE1? M3PScFFp MWTpcohq[mm2czDDdnQyKGGldHn2ZZRm\CClYYPwZZNmNTNuID23MEAuQCxiLUmsJIFv\CCyb3z5LGFFWC2{aXLvd4UqKHCxbInt[ZJie2V? NVrFRYxbOjN|MEK2OVA>
QGY7701 MXjBdI9xfG:|aYOgRZN{[Xl? MXGyOe69VQ>? MXWxMlVp Mlz6bY5pcWKrdIOgZYNkfW23bHH0bY9vKG:oIIP1Zk1IOSCyaHHz[UBqdmS3Y3XkJIJ6KESRWDCrJJF2\XKlZYTpci=> NGXNcnQzOzJ2MEC2NS=>
HepG2 Mn7MRZBweHSxc3nzJGF{e2G7 NHTF[4YzOM7:TR?= NWjyPJc3OzCvaX6= NYfHV|FXcW6qaXLpeJMhfGinIHXubIFv[2WmIHPlcIwh\GWjdHigZpkh[2:vYnnu[YQhfHKnYYTt[Y51KG:oIHHwbYdmdmmwIHHu[EBVWkGLTB?= NIm1bWYzOzJ{NEKzPS=>
U87  MmP0RZBweHSxc3nzJGF{e2G7 MY[yOe69VQ>? NVTYV5RYOmh? NVS3VIRR\GWlcnXhd4V{KGm|b3zpdZVqemm2aXflcolvKCiLU1ypMYlv\HWlZXSgZZBweHSxdHnjJINmdGxiZHXheIgtKGK3dDDuc5QhdmWlcn;0bYMh[2WubDDk[YF1cA>? MojENlMzOjl4Mk[=
HSC-2 M33XWWFxd3C2b4Ppd{BCe3OjeR?= NInEeIwzPS93MN88US=> NUHGOpZwOWh? Mk\IbY5pcWKrdIOgV24uOzhvaX7keYNm\CCleYTveI95cWOrdIm= Mkn3NlMyPTV{NEi=
HSC-4 Ml\YRZBweHSxc3nzJGF{e2G7 MYWyOU82OM7:TR?= M3WyZlFp MofybY5pcWKrdIOgV24uOzhvaX7keYNm\CCleYTveI95cWOrdIm= M2H0WVI{OTV3MkS4
CL-1 Mk\zRZBweHSxc3nzJGF{e2G7 MYOyNO69VQ>? MlPiNYg> NHLoVHRjdG:la4OgU3A1PDliaX7keYNm\CClZXzsJIRm[XSq Mn\QNlMyOzF5OEK=
MEL M4TPW2Fxd3C2b4Ppd{BCe3OjeR?= NEnv[Y8zOM7:TR?= M1O0WlI1cA>? MlTLSG1UVw>? NVTscFBPcW2yYXny[ZMhWDK[Nz3pcoR2[2WmIF3FUEBk\WyuIHHwc5B1d3Orcx?= NUSxUWxIOjNyMUS4PFc>
Bel-7402  M1T3[GNie3Cjc3WgRYN1cX[jdHnvckBCe3OjeR?= NHfpTlI2OM7:TR?= M3;1[lJp M3znSYlvcGmkaYTzJHBETS2rbnT1Z4VlKGGwb3nrbZM> NVHMOJNTOjNyMEi3OFI>
Eca-109 M1PXPGFxd3C2b4Ppd{BCe3OjeR?= NETpR2YzPc7:TR?= M2XhSFMxdWmw MlPhbY5pcWKrdIOgRmouSjFzLXnu[JVk\WRiY3XscEBl\WG2aB?= NFv2NVYzOzB5Nkm2Oy=>
MEL Ml\RRZBweHSxc3nzJGF{e2G7 MUKyNO69VQ>? NIL0VJUycA>? MnXOSG1UVw>? MWTpcZBicXKnczDQNng4NWmwZIXj[YQhVUWOIHPlcIwh[XCxcITvd4l{ MXGyN|AyPDh6Nx?=
Bel-7402  NFXJS2VCeG:ydH;zbZMhSXO|YYm= MlvhOVDPxE1? NIXKdlczcA>? MYTpcohq[mm2czDQR2UucW6mdXPl[EBidm:ra3nz NHPjSGozOzByOEe0Ni=>
L929 MmLDSpVv[3Srb36gRZN{[Xl? M4nqTVIvPc7:TR?= M4rIcVFp NGH3XodqdmO{ZXHz[ZMhWkmSMTDlfJBz\XO|aX;uJIFv\CCneHHj[ZJj[XSnZDDUUmbPuS2rbnT1Z4VlKG2rdH;jbI9v\HKrYXyg[Jl{\nWwY4Tpc44h[W6mIGLPV{Bxem:mdXP0bY9v MX:yN|AxODVzOB?=
RCC  M1H3XGNmdGxiVnnhZoltcXS7IFHzd4F6 NEXh[3MyODEQvF2= NX\vSGF{OjSq NEnJb5pz\WOxdnXy[ZMhfGinII\pZYJqdGm2eTDv[kBk\WyuczDlfJBwe2WmIITvJFE2\C2SR1qy NVfsXZM{OjJ7OUG0PVQ>
NB2a/d1 NWjhVXE5SXCxcITvd4l{KEG|c3H5 NUDGU2ZNOTByzszN MX:3Nog> NFi0Z|FifHSnboXheIV{KHO2YYXyc5Nxd3KrbnWtbY5lfWOnZDDjZZNx[XOnIHHjeIl3cXS7LDDQRXJRNCCjbnSgeIF2KGOuZXH2ZYdm NXjVdmFjOjJ7OEi1OFE>
T cell NIXFZ|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF[0N|UzPS1zMEFOwG0> MnfYNlRp MX\kc5NmNWSncHXu[IVvfGy7IHnubIljcXSnZDDUJINmdGxicILvcIln\XKjdHnvckBu\WSrYYTl[EB1cHKxdXfoJJRp\SClbz3zeIlufWyjdHnvckB4cXSqIHHueIkuS0R|IHHu[EBidnSrLVPENlg> M1PZUlIzQTh{NUO4
K562 MVnBdI9xfG:|aYOgRZN{[Xl? NWrXVFlnOTByzszN NHvQWGcycA>? MUnicI9kc3NiQXLuc4Jifmm|Y4XtxsBHNWmwZIXj[YQh[XCxcITvd4l{ MoPONlI6PzJ|N{K=
Jurkat  NHfyeWtCeG:ydH;zbZMhSXO|YYm= NV\XZlEyPDEQvF2= NFq5WW0ycA>? NGjicmhi[m:uaYPo[ZMhTmG|TD3pcoR2[2WmIHPhd5Bie2ViYXP0bZZifGmxbjDhcoQh[2WubDDk[YF1cA>? MX6yNlk1Ojd|OB?=
BGC-823 Mlq1RZBweHSxc3nzJGF{e2G7 MYOxNFDPxE1? NH:3SGUycA>? MXvwZZJ1cWGubImgdoV{[3WnczDj[YxteyCjZ3HpcpN1KGSjbXHn[UBw\iCmYXnkfoVqdg>? NVy2[W5{OjJ7Mk[1OFU>
Hep3B MWPBdI9xfG:|aYOgRZN{[Xl? M3r3e|Ux|ryP NH22T24ycA>? M2PEdYJtd2OtczDhdI9xfG:|aYOgbY5lfWOnZDDifUBJTUeFcx?= NE\SeJMzOjl{M{G1OC=>
LLC-PK1 NIS4dYpCeG:ydH;zbZMhSXO|YYm= MnvZNlDPxE1? M2S0cVFp NIDINIhxemW4ZX70d{BkcXOybHH0bY4ucW6mdXPl[EBl\We{YXTheIlwdiCxZjDBeIc2NCCkZXPsbY4uOSxiYX7kJGF1\zF{IIDyc5RmcW6| NIj6RmEzOjh7NkCzOy=>
A549 M3;FO2Fxd3C2b4Ppd{BCe3OjeR?= M3fUU|Ux|ryP M13N[VFp M3;4[IJtd2OtczD0bIUhSkGLLXnu[JVk\WRiYYDvdJRwe2m|wrC= MV2yNlg5PzJzNR?=
SGC-7901  Ml[wRZBweHSxc3nzJGF{e2G7 MWmxNO69VQ>? NVvVOYp[OjSq NFzscYJqdmirYnn0d{DPui{Qsj3kbY1mfGi7bHHjdplte2ira3;ubY4ucW6mdXPl[EBieG:ydH;zbZPDqA>? M122SlIzQDR6NUm3
DM6 M2TjZmFxd3C2b4Ppd{BCe3OjeR?= MlO5NVAx|ryP NGLSVpE4Omh? NX;HfI0z[myxY3vzJIJwfGhiRULGMVEh[W6mIFWySpRzNW2nZHnheIVlKGO7dH;0c5hq[2m2eR?= Mm\6NlI5OjV|Mki=
MCF-7, MDA-MB-468, Caco-2 NYrrUVZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVW1NO69VQ>? NVvjUFJnPDiq MnTSbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIHnubIljcXSrb36gbY5lfWOnZDDifUB{[XCxbnnu NXvI[5UxOjJ6MEC5Olg>
A2750  NYXrO5hvSXCxcITvd4l{KEG|c3H5 MVqyNO69VQ>? M3T3b|Jp MWnEUXNQ NGC1[YljdG:la4OgZ4F{eGG|ZTDjcIVifmGpZTDkeZJqdmdiaHXs[Y5idGmwIITy[YF1dWWwdDDhcoQhemWmdXPld{BifXSxcHjh[4lkKGOnbHyg[IVifGh? NGTkVWYzOjd6NEO2Ny=>
U87  NGnTflVCeG:ydH;zbZMhSXO|YYm= MkHUNlDPxE1? MkXrNlRp M1jPe5Jm\HWlZYOgeIhmKGGyb4D0c5NqeyC{YYTlJIlv\HWlZXSgZpkhWEyDQh?= NXv1XJI6OjJ5N{i3PFA>
HT1080 NH\KXo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHL5V|k2OM7:TR?= NU\E[XdoP2R? NYjyenUycW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJIlvcGmkaYTpc44h[2G3c3XkJIJ6KGOxbXLpcoVlKHS{ZXH0cYVvfCCxZjDER2Eh[W6mIF;NVC=> NV\iUZBCOjJ5NEC5PFQ>
A549  NFrlWGVCeG:ydH;zbZMhSXO|YYm= NEL1NmU2OM7:TR?= MmiwNog> M1jNb5BienSrYXzsfUBl\WO{ZXHz[ZMhe2:maYXtJJNmdGWwaYTlMYlv\HWlZXSgZZBweHSxc3nz NGfLWJczOjd{MUiwOC=>
Primary OPC Mn3yRZBweHSxc3nzJGF{e2G7 NUn1WmFkOc7:TR?= NIXFOG03cC9{NHi= M1PVPZJm\HWlZYOgeIhmKHCncnPlcpRi\2Vib3[gZ4VtdHNiaX6g[YFzdHlvIHHu[EBt[XSnLXHwc5B1d3Orcz;u[YNzd3Orcx?= M4e1e|IzPzB5M{i1
PMNs NUTnbFBpSXCxcITvd4l{KEG|c3H5 NHXpPGo1OM7:TR?= MYW2bC=> MlqwSG1UVw>? NYPPTI5yemW4ZYLz[YQhfGinIHHtc5VvfCCxZjDjcIVifmWmIHPhd5Bie2VvMzD0c{Bv\WG{II\lbIlkdGVibHX2[Yx{ M4GxVlIzPjl{NUe3
A549  MlS3RZBweHSxc3nzJGF{e2G7 MWG1NO69VQ>? NVK5[mFzOWh? M4W2dJBz\X[nboTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KEKjb3j1c5Nq\GViSR?= NHS2O3kzOjZ6N{[zOS=>
AGS MkLoRZBweHSxc3nzJGF{e2G7 M1fBU|Ix|ryP MVqxNog> MYHpcohq[mm2czD0bIUh[WO2aY\heIlwdiCxZjDwdo8u[2G|cHHz[U0{KGmwIILld5BwdnOnIITvJJRp\SCHdF;BZ{BnemGldHnvci=> MkLLNlI3QDd|OUi=
shC9  NWLFdZc1SXCxcITvd4l{KEG|c3H5 MkflNVDPxE1? MYOxOog> NI\KNGNjdHWwdIOgV2hJKGW6cILld5Nqd25iaX6gd4hEQSClZXzsd{BmgHCxc3XkJJRwKGWrdHjldkBRSSCxcjDMVGM> MYeyNlY1OTB7NB?=
primary MEFs M2\ZO2Z2dmO2aX;uJGF{e2G7 Ml7tNVJp M2XDO:KhcW6lcnXhd4V{KGW2b4Dvd4ll\S2rbnT1Z4VlKG2rdH;jbI9v\HKrYXygcYVu[nKjbnWg[IVxd2yjcnn6ZZRqd25? M4juT|IzPjF|N{[3
3T9 MEFs MoLJSpVv[3Srb36gRZN{[Xl? NGe0cG8yPmh? NVXkbZFxcW6lcnXhd4V{KGO7dH;jbJJwdWViYzDy[Yxm[XOnIHHmeIVzKGW2b4Dvd4ll\S22cnXheI1mdnR? MkHjNlI3OTN5Nke=
3T9 MEFs NXfMeHJXTnWwY4Tpc44hSXO|YYm= NFeyUGgyQGh? NVjUepFHfXC{ZXf1cIF1\XNiaX7peIlifG:{IHPhd5Bie2VvOTDieZQh\G:5boLl[5Vt[XSnczDl[oZm[3SxcjDjZZNx[XOnczDh[pRmeiCndH;wc5Nq\GVidILlZZRu\W62 MXyyNlYyOzd4Nx?=
MDA-MB-231  MlrGRZBweHSxc3nzJGF{e2G7 Mlq0NlDPxE1? MnTROIQ> NGjYeJVz\WS3Y3XzJJRp\SClZXzsJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KG2ndH\vdo1qdiC2cnXheI1mdnRid3HzJJNq\26rZnnjZY51dHl? NVLscnh2OjJ3OUO0OFE>
C6  NFL5N5RCeG:ydH;zbZMhSXO|YYm= MkH5NVDPxE1? M2LyclI1cA>? NVvZUlF6[myxY3vzJJRp\SC|dYDwdoV{e2m4ZTDl[oZm[3Rib3[geIhmKHCncITp[IUhd25idnnhZoltcXS7 NXrBdmtFOjJ3OEi5PFA>
HL-60  MnfGRZBweHSxc3nzJGF{e2G7 NYWyUlhxOTByzszN M2nFPFI1cA>? M1HNOIlvcGmkaYTzJJRp\SClZXzsJIFxd3C2b4Ppd{B{\WynY4Tl[EApMylvbXXueIh6dCEQsj2oNgKHmjZrLXTp[4x2[2:yeYLhco9{cWSnwrC1 MmLQNlI2PDZ4Nkm=
HL-60 NWnnWm1XSXCxcITvd4l{KEG|c3H5 NIDo[m8yOC16MN88US=> NIrxe4w1cA>? M17EZolvcGmkaYTzJHRIUFFvaX7keYNm\CClZXzsJIFxd3C2b4Ppd:Kh Mn;MNlI2OjN{Mkm=
BCC NFThOW9CeG:ydH;zbZMhSXO|YYm= NIXYbmE2OM7:TR?= MnHQNYg> MY\pcohq[mm2czDERXRUNW2nZHnheIVlKGe{b4f0bEBqdmirYnn0bY9v MYSyNlUyQTR|Nh?=
RAW 264.7 NVnGenVVSXCxcITvd4l{KEG|c3H5 NW\uXZNSPTBxMUCw{txO MknmNYg> M4\YNYNwdmOnboTyZZRqd25vZHXw[Y5l\W62IHnubIljcXS|IFTPUk1qdmS3Y3XkJJJTVkFiY3zlZZZi\2V? NXnWT3R1OjJ2OUG0NlY>
K562 MVvBdI9xfG:|aYOgRZN{[Xl? MkfGNlXPxE1? MVqybC=> NVf1Z4R3eHKndnXueJMh[XCxcITvd4l{KGmwZIXj[YQh[nliY3:teJJm[XSvZX70JJdqfGhiYX31doVve2mwIFegZY5lKFSUQVnM M2fMdVIzPDh|N{e3
SGC-7901 NIq3[lZCeG:ydH;zbZMhSXO|YYm= NV70NY9pOjBizszNxsA> NVHCOZRKOmh? MYfheJRmdnWjdHXzJGgzVzMEoH;yJHRPTiEQsT3pcoR2[2WmIHPlcIwh[XCxcITvd4l{KGG|IIflcIwh[XNiY3HzdIF{\S1|IHHjeIl3cXS7wrC= MnLmNlI1PzF3OEm=
PC3 NGXBe2hCeG:ydH;zbZMhSXO|YYm= Mm\LNVDPxE1? MlG5OIg> M{WzfoNwfW62ZYLzJIZt[X[xY3;4bYQucW6mdXPl[EBk[XOyYYPlMZJmdGG2ZXSgZZBweHSxc3nz MnThNlI1PzF7N{S=
SMMC-7721 Mn\TRZBweHSxc3nzJGF{e2G7 M1rU[VUx|ryP MmPrOFhp NXrHPGJq[XS2ZX71ZZRmeyCxVGKtbY5lfWOnZDDhdI9xfG:|aYO= MkjPNlI1PjV6M{O=
HeLa  MYDBdI9xfG:|aYOgRZN{[Xl? MVe1NOKh|ryP NHS4ZW41Nziq NVixPY5GcW6qaXLpeJMhW1SVLXnu[JVk\WRibHH0[U1xcGG|ZTDhdI9xfG:2aXOg[ZZmdnS| MU[yNlQ3ODVyNB?=
HeLa  MlfRRZBweHSxc3nzJGF{e2G7 MYi1NOKh|ryP MX[xbC=> NF7mW3J{fXCycnXzd4V{KHSqZTDGVmFRNWmwZIXj[YQh[WOldX31cIF1cW:wIH;mJIFvdmW6aX6gWkBxd3OrdHn2[UBk\Wyucx?= M1\DVVIzPDR7NESw
T47D  MWrBdI9xfG:|aYOgRZN{[Xl? NIfjdFcyODEQvF2= NVLjUGl4OWh? MnnnZoxw[2u|IITo[UBo\W6ncnH0bY9vKG:oIFWtZ4FlN0OWRkKgZpkhW1SV MUKyNlQxOTF4OB?=
HeLa  NYHINXNESXCxcITvd4l{KEG|c3H5 MoezN|DPxE1? M13GbVRp Mkj0xsBqdmO{ZXHz[ZMhfGinIHflcoVz[WxiY3XscEB3cWGkaXzpeJkhPDhiaDDh[pRmeiCyaH;0c4R6dmGvaXOgeJJm[XSvZX70xsA> NVq2NYhxOjJ|OUSyOFg>
HCC NX3NfY9[SXCxcITvd4l{KEG|c3H5 MUOyNEDPxE4EoB?= NVvZeY9qOmh? MlfuZZR1\W63YYTld{B1cGViRFjBJIlv\HWlZXSgZYN1cX[jdHnvckBw\iCSQWLQ M{fxSVIzOzR{N{Oy
mESCs MoTlRZBweHSxc3nzJGF{e2G7 M3;FTlIvPc7:TR?= NHjEUlczcA>? M2nnO4lvcGmkaYTzJJRp\SCQYV[tcYVlcWG2ZXSgZ4F{eGG|ZTDhZ5RqfmG2aX;u M3rzSVIzOjh3Mke0
EMT-6  NXnxZZROS3m2b4TvfIlkcXS7IFHzd4F6 MXWxNFDPxE1? MmHKNYg> NWfMdVI4eGG{dHnhcIx6KGKub3Pr[YQh[2WubDDk[YF1cCCrbnT1Z4VlKGK7IIPpdoFu\XOrbnW= MXKyNlI2OTl{MR?=
MCF7 MWXBdI9xfG:|aYOgRZN{[Xl? MXK1NOKh|ryP NHf3cHEycA>? MVzpcohq[mm2czDQRUBi[3SrdnH0[YQh[2G|cHHz[U0{NCBvOTygZY5lKHCxbImoRWRRNXKrYn;z[UkheG:ueX3ldoF{\Q>? NWTvV2FiOjJ{MkOzOFU>
K562 NHjhc5BCeG:ydH;zbZMhSXO|YYm= MoD2NlAh|ryPwrC= M2PxSlQ5cA>? MljESG1UVw>? M3m3eIJtd2OtczDsZZBifGmwaXKtbY5lfWOnZDDpcohq[mm2aX;uJI9nKH[rYXLpcIl1gSCjbnSgZZBweHSxc3nzJIlv\HWldHnvci=> M4L0OlIzOjF4MUW4
Molt4-hyg NUPLTVFxSXCxcITvd4l{KEG|c3H5 NILYU5MyOM7:TR?= MXOwMlVp MWLicI9kc3NiZnHycoV{d2xvaX7keYNm\CClYYPwZZNmNTNvbHnr[UBi[3Srdnn0fS=> NXPZWZFmOjZ{N{W4NVE>
HeLa NFTNd3dCeG:ydH;zbZMhSXO|YYm= M3z0[FEx|ryP NEnjUo8xNjWq NYrHU4dGcW6qaXLpeJMh[XCxcITvd4l{KGmwZIXj[YQh[nlidHjlJINwdWKrbnXkJJRz\WG2bXXueEB4cXSqIHfvcYl{cW5iTjDhcoQhXFKDSVy= MXuyNlE4QTZ4MR?=
Jurkat T NW\tWoJ4SXCxcITvd4l{KEG|c3H5 NWTxNY5oOzEQvF2= NUnLZVQ5OC53aB?= M17kd2ROW09? MWDicI9kc3NidHjlJJpqemGvLXnu[JVk\WRiYYDvdJRwe2m| MYSyNlE2QTh7OB?=
Neutrophil MmnwRZBweHSxc3nzJGF{e2G7 M4i1XVIx|ryP MYGwMlVp MVfheJRmdnWjdHXzJJRp\SCycn:tZZBweHSxdHnjJIVn\mWldDDv[kBO[VJz MlTxNlYyQTZ6NES=
HCT116 NYniN|RYSXCxcITvd4l{KEG|c3H5 M1H5fVUxyqEQvF2= MofFNog> MXny[ZZmenOnczDzfY5memerc4TpZ{BieG:ydH;zbZMh\W[oZXP0d{Bw\iClZXzlZ495cWJiYX7kJG5RSy1zNtMg M4DIWlIzOTV7N{Wy
MDA-MB-231  MmHIRZBweHSxc3nzJGF{e2G7 NFnCSokzNjVvNz61{txO M4jwe|Jp MVvpcohq[mm2czD0bIUh[2WubDDk[YF1cCCxZjDNSGEuVUJvMkOxJINmdGy|IHnu[JVk\WRiYomgV2RVKGmwIHGgZ49v[2WwdILheIlwdiCmZYDlcoRmdnRibXHucoVz MknkNlIyOTV3Mk[=
LNCaP MVnBdI9xfG:|aYOgRZN{[Xl? MkDnOFDPxE1? MVuybC=> MX\pcohq[mm2czDieZRmcW5iaX7keYNm\CClZXzsJIFxd3C2b4Ppdy=> NWfLUFlOOjJzMUS3OlQ>
MB231 NULF[JZMSXCxcITvd4l{KEG|c3H5 NYrmSYpHOTByzszN NFzzUGMycA>? MmixSG1UVw>? M3PJXYFjem:pYYTld{B1cGViaX7keYN1cW:wIH;mJINmdGxiZHXheIgh[nliV1XFNUBqdmirYnn0bY9vNCCWUlHJUEB1emWjdH3lcpQtKGGwZDD0bIUh[2:vYnnuZZRqd25? M{HKT|IzOTF{OUSw
HCC38  NHHmVYFCeG:ydH;zbZMhSXO|YYm= M4O5U|ExOM7:TR?= NUj6XGNIOWh? NIS4eVJFVVOR NW\jboIy[WK{b3fheIV{KHSqZTDpcoR2[3Srb36gc4Yh[2WubDDk[YF1cCCkeTDXSWUyKGmwaHnibZRqd25uIGTSRWlNKHS{ZXH0cYVvfCxiYX7kJJRp\SClb33ibY5ifGmxbh?= M2TMSVIzOTF{OUSw
MDA-MB231 M3LLW2Fxd3C2b4Ppd{BCe3OjeR?= NFX5fIg2OMLizszN M3KwVVI1cA>? NYO3dlhJTE2VTx?= NWfxV4xZ[WK{b3fheIV{KGO3cnP1cYlvNWmwZIXj[YQh[2WubDDk[YF1cA>? M4rwTVIzOTBzM{O1
LNCaP NV7lfXhYSXCxcITvd4l{KEG|c3H5 M2PxOFUxyqEQvF2= MV2yOIg> NYT2NFdRTE2VTx?= M{Xm[YFjem:pYYTld{BkfXKldX3pck1qdmS3Y3XkJINmdGxiZHXheIg> NVXD[FB4OjJzMEGzN|U>
HCT116 NYi3c3NNSXCxcITvd4l{KEG|c3H5 NYrycG42PTEEoN88US=> Mk\xNlRp MYfEUXNQ Ml3KZYJzd2ejdHXzJIN2emO3bXnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=> M3L6NlIzOTBzM{O1
Ishikawa  MlLURZBweHSxc3nzJGF{e2G7 MlXENlXPxE1? NVy1[XJ{OjSq NHz2VZZz\WS3Y3XzJINmdGxiZHXheIgh[W6mIHHwc5B1d3OrczDpcoR2[2WmIHL5JGJi\iCDMR?= MnjONlIxQDh7MUi=
 YD-8  NX3vUmxxSXCxcITvd4l{KEG|c3H5 M{X2UFExOM7:TR?= MYGxbC=> MkDTbY5pcWKrdIOgVGxGVy2rbnT1Z4VlKGGyb4D0c5Nqew>? M3nsNVIzODh4MUiz
eosinophil  M33UN2Fxd3C2b4Ppd{BCe3OjeR?= M4XrdVkx|ryP NVvJRop5OjSq MV\pcohq[mm2czDhdI9xfG:|aYOgbY5lfWOnZDDifUBH[XNiYX70bYJw\HoEoB?= Ml7QNlIxPzl|M{S=
L929 MmXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fKXlIvPc7:TR?= M2nEclI1cA>? MWPpcohq[mm2czD0bIUh\XiycnXzd4lwdiCxZjDwMZA{QCCjbnSgUmYu|rqEIITvJIF2\22nboSgWG5H|rFvaX7keYNm\CCwZXPyc5B1d3OrczDhcoQh[XW2b4DoZYd6 NVLmRnYyOjJyMkewPVc>
YD-8  MkjWRZBweHSxc3nzJGF{e2G7 MYexNFDPxE1? NFe0ZXkycA>? MVXicI9kc3NidHjlJGdUNUiFbD3pcoR2[2WmIHHwc5B1d3Orcx?= NFG3dJozOjB{MEC3PC=>
HBx NY\WeWJGSXCxcITvd4l{KEG|c3H5 MX2yOe69VQ>? MU[0PIg> M4PscWROW09? M3niVZJm\HWlZXSgZ4VtdCCmZXH0bEBqdmS3Y3XkJIJ6KDNvTVG= MYWyNlAzODB5OB?=
U937  MnTsRZBweHSxc3nzJGF{e2G7 MXW1NOKh|ryP NWHa[Wc1OWh? M1KwVIlvcGmkaYTzJGhHNWmwZIXj[YQh[XCxcITvd4l{yqB? NHjqN|czOTl7OEezNS=>
HL60 M3HPSWFxd3C2b4Ppd{BCe3OjeR?= MY[0NO69VQ>? NUnXR25kPDCvaX6= MX;EUXNQ NHvxXXJjdG:la4OgRm5FSyClb33wc5Vv\HNiaX7keYNmKGW6cH;zeZJmKG:oIIDoc5NxcGG2aXT5cJNmemmwZTDhcoQhTE6DIH\yZYdu\W62YYTpc44> NYXPO4hsOjF7OEOyPVY>
M-14 Mn7BRZBweHSxc3nzJGF{e2G7 MmHDNlXPxE1? MlvYNE42cA>? M3LFPeKhcW6qaXLpeJMh[m:2aDD0bIUh[3K3ZHWg[Zh1emGldD2gZY5lKGOxbYDveY5lNWmwZIXj[YQh[XCxcITvd4l{ MkDRNlE6PTR7NUm=
SK-BR-3 NHTJTGhCeG:ydH;zbZMhSXO|YYm= NVXYco1rPTEEoN88US=> NHq4[oQzcA>? NFTMXGdjdG:la4OgZZBweHSxdHnjJGRPSSCocnHncYVvfGG2aX;uJIlv\HWlZXSgZpkh[2:vYnnuZZRqd25ib3[gV20uOTZ2IHHu[EBz[WSrYYTpc44> MWOyNVkxOTN6Nh?=
MDA-MB-468 NET5SG5CeG:ydH;zbZMhSXO|YYm= MnSzOVDDqM7:TR?= NV;GZXhzOmh? MVzicI9kc3NiYYDvdJRwfGmlIFTORUBnemGpbXXueIF1cW:wIHnu[JVk\WRiYomgZ49u[mmwYYTpc44hd2ZiU12tNVY1KGGwZDDyZYRq[XSrb36= NED0NmQzOTlyMUO4Oi=>

... Click to View More Cell Line Experimental Data

In vivo In vivo Z-VAD-FMK administration has been shown previously to be nontoxic and to prevent apoptosis in animal models. Intraperitoneal HK-GBS injection leads to preterm delivery, and pretreatment with Z-VAD-FMK delays preterm delivery in mice. In OVA-sensitized mice,treatment of z-VAD-fmk inhibits allergen-induced leukocyte infiltration. Systemic injection of the pan-caspase inhibitor z-VAD-fmk immediately before OVA challenge reduced inflammatory cell accumulation, mucus hypersecretion, and Th2 cytokine release in OVA-sensitized/challenged mice. Treatment with z-VAD-fmk blocked terminal differentiation of lens epithelial cells and keratinocytes, the differentiation of monocytes into macrophages, and the differentiation of erythroid progenitors. z-VAD-fmk attenuated allergen-induced airway inflammation and hyperreactivity. Treatment with z-VAD-fmk in vivo also prevented subsequent T cell activation ex vivo[7].

Protocol

Cell Research:

[6]

+ Expand
  • Cell lines: human granulosa cell lines (GC1a, HGL5, COV434)
  • Concentrations: 50 μM
  • Incubation Time: 48 h
  • Method:

    To validate the efficacy of Z-VAD-FMK, three human granulosa cell lines (GC1a, HGL5, COV434) were treated for 48 h with etoposide (50 μg/ml) and/or Z-VAD-FMK (50 μM) under normoxic conditions. To mimic the ischemic phase that occurs after ovarian fragment transplantation, cells were cultured without serum under hypoxia (1 % O2) and treated with Z-VAD-FMK. The metabolic activity of the cells was evaluated by WST-1 assay. Cell viability was determined by FACS analyses. The expression of apoptosis-related molecules was assessed by RT-qPCR and Western blot analyses.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: CD1 mice
  • Formulation: dissolved in DMSO, diluted in PBS (final concentration of DMSO < 1%)
  • Dosages: 10 mg/kg
  • Administration: i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 93 mg/mL (198.93 mM)
Water Insoluble
Ethanol Insoluble warmed
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+35 %PEG 300+2%Tween 80+ddH2O
For best results, use promptly after mixing.
6mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 467.49
Formula

C22H30FN3O7

CAS No. 187389-52-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Can you suggest an in vivo formulation of S7023 for animal studies?

  • Answer:

    For in vivo study of S7023, The IP formulation is 2% DMSO+35 % PEG 300+2% Tween 80+ddH2O up to 6 mg/ml. The gavage formula is 1%CMC-Na up to 30 mg/ml (suspensions).

  • Question 2:

    What is difference between S7023 & S8102?

  • Answer:

    Unlike S7023, S8102 does not require pretreatment with esterase for in vitro studies. This information was cited from the article: https://www.ncbi.nlm.nih.gov/pubmed/16973565.

Caspase Signaling Pathway Map

Related Caspase Products0

Tags: buy Z-VAD-FMK | Z-VAD-FMK supplier | purchase Z-VAD-FMK | Z-VAD-FMK cost | Z-VAD-FMK manufacturer | order Z-VAD-FMK | Z-VAD-FMK distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID